COMMITTED TO DISCOVERING BEST-IN-CLASS THERAPIES
TO CONQUER INFLAMMATORY and immunologic DISEASES

RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

November 06, 2025



« back to news page